Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers
Iluzanebart demonstrated favorable safety, tolerability, pharmacokinetics, and pharmacological activity in the CNS, supporting further clinical development for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
Authors
- Andreas Meier (ORCID: https://orcid.org/0000-0002-3135-9310)
- Spyros Papapetropoulos
- Andrew Marsh
- Marco Colonna (ORCID: https://orcid.org/0000-0001-5222-4987)
- Kelly Neelon
- Ryan O'Mara
- Evan A. Thackaberry (ORCID: https://orcid.org/0000-0001-7161-6361)
- David Stiles
- Raj Rajagovindan
Institutions
- Washington University in St. Louis (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/acn3.70033
- Citations
- 1
- Primary Topic
- Inflammation biomarkers and pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.80